Bicycle Therapeutics and ThromboGenics form an alliance to develop bicycle peptide inhibitors for the treatment of ophthalmic diseases

Bicycle Therapeutics, a next generation biotherapeutics company developing novel bicyclic peptides, today announced that it has entered into a collaboration and license agreement with ThromboGenics NV to develop potent and selective bicyclic peptide inhibitors against a specific drug target of interest for the treatment of ophthalmic diseases, such as diabetic macular edema (DME).

Bicycle Therapeutics announces expansion of management team with appointments of CSO and Business Development Director

Bicycle Therapeutics, a next generation biotherapeutics company developing novel bicyclic peptides, today announced the appointment of Christophe Bonny as Chief Scientific Officer and Jonathan Savidge as Business Development Director. This expansion to the management team reflects the successful development of the company and its technology to the next stage in its evolution.

Bicycle Therapeutics announces £3.75 million financing for drug discovery

Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it had secured a tranched equity financing of £3.75 million to invest in selection of drug candidates using its bicyclic peptide technology platform. Current investors Atlas Venture, Novartis Venture Fund, SR One and SV Life Sciences were joined by new investor Astellas Venture Management, the venture capital arm of Astellas Pharma.

Bicycle Therapeutics appoints Rolf H. Günther, MD, PhD as CEO

Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced the appointment of Rolf Günther, MD, PhD as Chief Executive Officer. Bicycle Therapeutics has developed a proprietary bicyclic peptide technology that enables the discovery of a new class of drug candidates with antibody-like selectivity and specificity that can be manufactured with economics similar to new chemical entities. Under Dr Günther’s leadership, the company will apply the technology to drug discovery projects addressing a wide range of challenging targets, through its own programmes and by entering into corporate partnerships.